Bryan R. Lawrence
Oakcliff Capital Partners
Bryan R. Lawrence Cardlytics Inc stake
total: 26
Oakcliff Capital Partners CDLX trades
- Total transactions:
- 8
- New positions:
- 1
- Sold out:
- 1
- Added:
- 4
- Reduced:
- 2
- Held since:
- 2019 Q3
- Held for:
- 12 quarters
- Latest activity:
- 2022 Q3
According to 2026 Q1 report, Bryan R. Lawrence doesn't hold any Cardlytics Inc (CDLX) shares. To date, the estimated cost basis is nearly $393.23 for "buy" trades and estimated average "sell" price is $464. Oakcliff Capital Partners first purchased CDLX in 2019 Q3, initially acquiring 28,106 shares. Since the initial investment in Cardlytics Inc (CDLX), Oakcliff Capital Partners has made 7 more transactions.
When did Bryan R. Lawrence sell Cardlytics Inc (CDLX)?
Bryan R. Lawrence sold off the entire Cardlytics Inc (CDLX) position in 2022 Q3.
When did Bryan R. Lawrence buy Cardlytics Inc (CDLX)?
Bryan R. Lawrence first invested in Cardlytics Inc (CDLX) in 2019 Q3 at the reported quarter-end price of $335.19 per share.
What's the cost basis of Oakcliff Capital Partners's CDLX stake?
The estimated cost basis for Cardlytics Inc (CDLX) stake is around $393.23 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $393.23
- Weighted AVG sell price:
- $464.00
Bryan R. Lawrence's historical trades in Cardlytics Inc
8 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2022 Q3
|
0.00%
|
0
|
$223.11
|
|
-100% (-33,973.6)
|
-5.59%
|
|
2022 Q2
|
5.59%
|
33,973.6
|
$223.11
|
$7,580,000
|
+11.49% (+3,500)
|
+0.58%
|
|
2021 Q4
|
9.20%
|
30,473.6
|
$660.90
|
$20,140,000
|
+12.26% (+3,328.9)
|
+1.01%
|
|
2021 Q3
|
10.09%
|
27,144.7
|
$839.39
|
$22,785,000
|
+14.80% (+3,500)
|
+1.3%
|
|
2021 Q1
|
12.30%
|
23,644.7
|
$1,096.99
|
$25,938,000
|
-12.39% (-3,344.8)
|
-1.46%
|
|
2020 Q4
|
15.30%
|
$1,427.70
|
-18.91% (-6,295)
|
|||
|
2020 Q1
|
8.14%
|
$349.59
|
+18.42% (+5,178.1)
|
|||
|
2019 Q3
|
6.37%
|
$335.19
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.